Update on Pathologic and Radiologic Diagnosis of Combined Hepatocellular-Cholangiocarcinoma
Article information
Abstract
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a malignant primary liver carcinoma characterized by the unequivocal presence of both hepatocytic and cholangiocytic differentiation within the same tumor. Recent research has highlighted that cHCC-CCAs are more heterogeneous than previously expected. In the updated consensus terminology and WHO 2019 classification, “classical type” and “subtypes with stem-cell features” of the WHO 2010 classification are no longer recommended. Instead, it is recommended that the presence and percentages of various histopathologic components and stem-cell features be mentioned in the pathologic report. The new terminology and classification enable the exchange of clearer and more objective information about cHCC-CCAs, facilitating multi-center and multi-national research. However, there are limitations to the diagnosis of cHCC-CCA by imaging and biopsy. cHCC-CCAs showing typical imaging findings of HCC could be misdiagnosed as HCC and subjected to inappropriate treatment, if other clinical findings are not sufficiently considered. cHCC-CCAs showing at least one of the CCA-like imaging features or unusual clinical features should be subjected to biopsy. There may be a sampling error for the biopsy diagnosis of cHCC-CCA. An optimized diagnostic algorithm integrating clinical, radiological, and histopathologic information of biopsy is required to resolve these diagnostic pitfalls.
INTRODUCTION
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver cancer (PLC) showing both hepatocytic and cholangiocytic differentiation, it reportedly accounts for about 1–5% of all PLCs.1–3 Given the heterogeneous histopathologic nature of cHCC-CCAs, imaging or biopsy diagnosis is challenging, and the ideal diagnostic strategy for cHCC-CCAs in non-surgical candidates is not sufficiently well defined. Despite several recent investigations, the pathogenesis, histopathology, and genetics of this enigmatic tumor have not been fully understood. Reflecting on the current understanding, the consensus terminology of cHCC-CCA was published in 2018, and the WHO classification of cHCC-CCA was revised in 2019.1,4 Herein, we aimed to comprehensively review the updated information on the pathologic and radiologic diagnosis of cHCC-CCAs.
THE 2018 UPDATED CONSENSUS TERMINOLOGY AND WHO 2019 CLASSIFICATION
In the updated 2018 consensus terminology and WHO 2019 classification,1,4 cHCC-CCA is defined as a PLC with the unequivocal presence of both hepatocytic and cholangiocytic differentiation within the same tumor, similar to WHO 2010 classification. cHCC-CCA is characterized by complex morphological and immunophenotypical features and can be diagnosed regardless of the percentage of each component if the components are present unequivocally. However, multi-focal HCC or CCA, collision of HCC and CCA arising separately, any form of hepatoblastoma or variants, pediatric transitional liver cell tumor or variants, and HCC or CCA with neuroendocrine components should not be classified as cHCC-CCAs.
In the WHO 2010 classification, cHCC-CCAs were categorized as “classical type” and three subtypes with stem-cell features, including “typical subtype,” “intermediate-cell subtype,” and “cholangiolocellular subtype”.5 However, criticisms have been raised about the stem cell subtypes. Tumor cells with stem/progenitor cell features can be observed in most cHCC-CCAs, including the classical type. Besides, some PLCs can display two or more histologic components and often do not match the specific subtype of the WHO 2010 classification.6,7 Therefore, in the updated WHO 2019 classification, the use of “cHCC-CCA with stem-cell feature” is no longer recommended.8 It is recommended that the presence and percentages of various histopathologic components and stem-cell features be mentioned in the pathologic report.
Cholangiolocarcinoma (CLC) comprises tumor cells resembling cholangioles (canals of Hering), where the hepatic stem/progenitor cells are located.9,10 CLC also shows enriched CCA-like features and the absence of HCC-like features in the molecular profile, which is distinct from the phenotypes of other stem-cell subtypes of cHCC-CCA.11 However, recent morphometric and immunohistochemical (IHC) analyses revealed that the CLC originated not from the cholangiole but the interlobular bile duct.12 In the updated WHO 2019 classification, the CLC is classified as cHCC-CCA only when it is mixed with HCC or intermediate carcinoma. However, if the CLC component exists alone or is mixed with CCA only, it is classified as CCA, not cHCC-CCA.
Intermediate cell carcinoma is composed of tumor cells showing intermediate features between hepatocytes and cholangiocytes at the cellular level, and it displays both hepatocytic and cholangiocytic IHC markers. PLCs comprising only intermediate cells are diagnosed as intermediate cell carcinoma, and those showing mixed intermediate cell carcinoma and other types of tumors (HCC, CCA, or CLC) are classified as cHCC-CCAs. Further studies are needed to clarify whether intermediate cell carcinoma is a distinct clinicopathological entity rather than a histopathological spectrum.
The diagnosis of cHCC-CCA should be based on the histomorphology on hematoxylin-eosin stain. There are occasions when it is not easy to assess the HCC or CCA area based on histomorphology, especially when the tumor is poorly differentiated, and in such case, immunohistochemistry can be useful to confirm hepatocytic and/or cholangiocytic differentiation. However, the expression of IHC markers alone, without the corresponding histomorphologic features, is not adequate for diagnosis. IHC markers for hepatocytic differentiation include HepPar-1 (75–85% positivity), Arginase-1 (85–95% positivity), polyclonal carcinoembryonic antigen (CEA) with canalicular expression (50–80% positivity), CD10 with canalicular expression (50–75% positivity), and alpha-fetoprotein (AFP) (30% positivity), among others; IHC markers for cholangiocytic differentiation include K7 (>90% positivity), K19 (>75% positivity) and Ep-CAM (>90% positivity), among others. A wide variety of IHC markers, including K19, EpCAM, CD56, KIT, and CD133, have been used to confirm the stem/progenitor cell phenotype. Some of these markers, including K19, EpCAM, and CD56, can also be expressed in cholangiocytes at various development stages. Therefore, it is important that these antibodies be used and interpreted by an experienced pathologist, taking into account the tumor histomorphology.
PATHOGENESIS OF cHCC-CCA
The pathogenesis of cHCC-CCA remains elusive. Two possibilities have been postulated regarding the pathogenesis of cHCC-CCA: 1) trans-differentiation of HCC or CCA into the other component, and 2) derivation of cHCC-CCA from the hepatic stem/progenitor cell.13 cHCC-CCAs often show tumor cell components with stem-cell features, and thus, liver stem/progenitor cells have been proposed as a potential origin of cHCC-CCAs.14 Recently, increasing clinical and experimental evidence indicated that cHCC-CCA could result from plasticity or the dedifferentiation of PLC. In a mouse model, PLCs from the same cell of origin were suggested to show various hepatocytic/cholangiocytic differentiation and stem-cell features,15 and advanced HCC was reported to show molecular and pathologic features of CCA.16 Among PLCs treated with trans-arterial chemoembolization, the occurrence of cHCC-CCA was reported, suggesting the potential microenvironmental regulation of tumor trans-differentiation. 17
MOLECULAR FEATURES OF cHCC-CCA
Despite recent active investigations since early 2000, the genetic and molecular features of cHCC-CCA remain unclear. The recently reported molecular features of cHCC-CCAs are summarized in Table 1; these are significantly heterogenous. It should be noted that these studies were performed on a limited series, reflecting the low frequency of this tumor. A genetic study of each microdissected component of cHCC-CCA revealed that HCC and CCA components shared genetic and chromosomal aberrations in most cases, suggesting a single clonal origin.11,18–20 Several studies have reported that the mutation profile of cHCC-CCA is similar to that of CCA.21 In contrast, more recent studies have reported that the mutation profile is rather similar to that of HCC.20,22,23 Moeini et al.11 studied gene expression via unsupervised clustering and reported the molecular features of classical, stem cell, and CLC types. Concerning the background liver, the genome-wide substitution patterns of cHCC-CCAs with chronic hepatitis overlapped with HCCs, whereas those of hepatitis-negative cHCC-CCAs were diverse. 22 These findings suggest that the genetic characteristics of cHCC-CCAs are heterogeneous, similar to their histopathologic features.
CLINICAL CONSIDERATIONS IN THE DIAGNOSIS OF cHCC-CCA
As with HCCs, cHCC-CCAs show male predominance. In cHCC-CCA, the incidence of chronic hepatitis and cirrhosis is 23–38% and 50–62%, respectively; these ratios are similar to those of HCC,24–27 or intermediate between those of HCC and CCA.24–31 Previously, a low incidence of chronic hepatitis/cirrhosis was reported in western series;32 however, in recently reported country-wide data from the United States, the incidence of chronic hepatitis/cirrhosis is similar to that in HCC. The etiologies of chronic hepatitis/cirrhosis include hepatitis B (27–80%), hepatitis C (4–38%), or alcoholic liver disease (6–36%).24–31 The chronic hepatitis and cirrhosis are risk factors not only for HCCs but also for CCAs.33 However, the association of cHCC-CCAs with other risk factors for CCAs, including parasitic fluke, primary sclerosing cholangitis, and choledocholithiasis, remains unknown.
Serologic markers, including AFP, CEA, and carbohydrate antigen 19-9 (CA19-9), are often evaluated when a PLC is suspected. In cHCC-CCA, serum AFP was reported to be similar to that in HCC and higher than that in CCA in most reports;29–32,34,35 however, in some reports, the lower AFP levels were reported to be similar to that in CCAs.36 Varying levels of serum CA19-9 in cHCC-CCAs have been reported; these were not significantly higher than those in HCCs.27,36,37 The serum CEA level in cHCC-CCA was not significantly different from that in HCC.27,29,32 Discordant serologic tumor marker levels and imaging findings may be a clue to the diagnosis of cHCC-CCA.38
RADIOLOGIC DIAGNOSIS OF cHCC-CCA
The primary goal of imaging diagnosis of PLC is to distinguish HCC from other PLCs, including cHCC-CCA and CCA. In high-risk individuals for HCC, typical imaging findings of HCC (arterial enhancement and washout, or LR-5 of Liver Imaging and Reporting and Data System [LI-RADS]) show very high positive predictive value for HCC; therefore, most HCC management guidelines allow imaging diagnosis of HCC without biopsy in those patients.39,40 The definition of high-risk individuals is similar across guidelines with minor differences. Individuals with chronic hepatitis B or cirrhosis of any cause are included in the high-risk category according to most guidelines.39 Most patients with cHCC-CCA can also be included in the high-risk category, as the incidence of chronic hepatitis and cirrhosis in such patients is similar or slightly lower than that in patients with HCC. When PLC is suspected in patients who are not at high risk for HCC, the lesion should be subjected to biopsy, and not imaging diagnosis alone. LI-RADS is an imaging diagnostic algorithm for HCC, integrated into the American Association for the Study of Liver Diseases (AASLD) guideline.40,41 We can categorize the observations into the following LI-RADS categories: LR-1 (definitely benign), LR-2 (probably benign), LR-3 (intermediate probability of malignancy), LR-4 (probably HCC), LR-5 (definitely HCC), and LR-M (probably or definitely malignant, not necessarily HCC). When a hepatic lesion is categorized as LR-5, it can be diagnosed as HCC without a biopsy. When the lesion is categorized as LR-M, a biopsy is recommended for confirmative diagnosis. The computed tomography (CT) and magnetic resonance imaging (MRI) findings of the recently reported cHCC-CCA are summarized in Table 2. The radiologic appearance of cHCC-CCA can resemble either HCC or CCA; therefore, cHCC-CCA is often misdiagnosed as HCC or CCA.42 The arterial enhancement pattern on CT or MRI is one of the most critical imaging features that distinguishes HCC from other PLCs. HCCs often show non-peripheral enhancement in the arterial phase, whereas CCAs often show peripheral (rim-like) enhancement. For cHCC-CCA, the most common arterial phase enhancement pattern is a peripheral enhancement, seen in approximately 39–100% of cHCC-CCAs (Fig. 1, 2).38,42–48 However, approximately 40–59% of cHCC-CCAs exhibit a non-peripheral enhancement pattern in the arterial phase.24,42,43,45,47 The washout and capsular appearance are major features that, in conjunction with non-peripheral enhancement, are suggestive of HCC; they are reported to be observed in 27–67% and 9–28% of cHCC-CCAs, respectively (Fig. 3).24,38,42,43,45,47,48
Although a considerable number of cHCC-CCAs show major features suggesting HCC, the ancillary features suggesting a non-HCC malignancy should also be taken into account to reduce misdiagnosis. These ancillary features, called LR-M features, include targetoid appearance (peripheral arterial enhancement, peripheral washout, and delayed central enhancement), marked diffusion restriction, and infiltrative appearance. Potretzke et al.45 reported that 54% (33/61) of cHCC-CCAs showed major features typical of HCC, but 88% (29/33) of them demonstrated at least one LR-M feature. Lee et al.49 reported that at least one LR-M feature was observed in 94% (31/33) of cHCC-CCAs and 51% (34/66) of HCCs. It was suggested that cHCC-CCA could be diagnosed with a sensitivity of 55% and specificity of 94% when the lesion exhibits three or more LR-M features. Other recent studies reported that 61% of cHCC-CCAs were classified as LR-M and 23–36% as LR-5.47,48 When cHCC-CCAs are categorized as LR-5, they might lead to inappropriate treatment strategies.
HCC-like or CCA-like (LR-M) imaging features do not always reflect the dominant histologic component of cHCC-CCA. HCC-dominant cHCC-CCA might show peripheral arterial enhancement, and CCA-dominant cHCC-CCA might exhibit global enhancement.24,50 Interestingly, several recent reports have proposed that cHCC-CCAs with HCC-like imaging patterns demonstrate a better prognosis than those with a CCA-like imaging pattern. The imaging pattern is a better surrogate than the histologic pattern for predicting outcome after hepatic resection.24,48,50,51 The clinical, histological, and radiological characteristics of PLCs are summarized in Table 3.
BIOPSY DIAGNOSIS OF cHCC-CCA
As only part of the tumor tissue can be sampled by percutaneous biopsy, there is an effect of sampling on the diagnosis of cHCC-CCA (Fig. 4). For those cases of cHCC-CCA composed predominantly of HCC or CCA area, the other components might not be included in the biopsied tissue, making a sampling error leading to an incorrect diagnosis. Gigante et al.52 studied 21 cases of biopsy-resection-matched cHCC-CCAs. They found that only 48% (10/21) of cHCC-CCAs were diagnosed correctly by biopsy. The remaining 52% (11/21) cHCC-CCAs were misdiagnosed as CCAs or HCCs. The expression of IHC markers often show similar patterns in biopsied and resected tumor tissues, which may help in the diagnosis of cHCC-CCA in biopsy specimens.52,53 Besides, there is little knowledge on whether radiologic imaging can distinguish various histologic components. Even if possible, small tumor areas with different histologic components might be difficult to obtain by image-guided biopsy.
CONCLUSION AND FUTURE PERSPECTIVES
There are still many unknowns in the pathogenesis, histopathology, and genetics of cHCC-CCAs. Recent research has highlighted that cHCC-CCAs are more heterogeneous than previously expected. The recently updated consensus terminology and the WHO 2019 classification for cHCC-CCAs, enabling clear and informative descriptions, are expected to facilitate multi-center and multi-national research.
Most cHCC-CCAs arise in the background of chronic hepatitis or cirrhosis; therefore, the primary differential imaging diagnosis is HCC. cHCC-CCAs showing typical imaging findings of HCC can be misdiagnosed and subjected to inappropriate treatment if other clinical findings are not adequately considered. Using only imaging modalities may lead to misdiagnosis of cHCC-CCAs with minor histologic components. Nevertheless, several reports have demonstrated the prognostic significance of imaging findings of cHCC-CCA, suggesting that imaging is a useful clinical decision-making tool at the preoperative stage.
As most cHCC-CCAs show at least one LR-M (CCA-like) imaging feature in addition to those of HCC, it is often subjected to biopsy for diagnosis. However, there may be sampling error, as only a part of the tumor tissue is sampled during biopsy. For appropriate pathologic diagnosis of cHCC-CCAs, surgical specimens including all tumor components, even minor ones, are preferred. It is necessary to develop an optimal diagnostic algorithm using clinical, radiologic, and histopathologic biopsy information. Several retrospective single-center studies attempted to optimize radiological criteria utilizing LR-M features, combining radiologic and serologic findings, or combining radiological findings and biopsy results.38,49,52 Because these criteria do not have sufficient diagnostic accuracy for cHCC-CCAs, further optimization and external validation are required. Furthermore, the discovery of non-invasive molecular surrogates, such as novel serum markers, could be a solution for overcoming various obstacles in the diagnosis of cHCC-CCA.
Notes
FINANCIAL SUPPORT
This study was supported by Korean Liver Cancer Association Research Award (recipient: H. R.).
Conflicts of Interest
The authors declare no conflicts of interest relevant to this article.